Centrum Broking: Aarti Drugs Delivers Stellar Q2 Performance; Strong Growth Outlook
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Centrum Broking Report
Aarti Drugs Ltd.’s Q2 FY21 results continued to deliver stellar performance. The earnings were marginally ahead of our estimates.
The active pharmaceutical ingredient industry has experienced overall sustained price inflation across product baskets and strong volume demand.
Most of the pharma players across the globe are working on securing most reliable APIs sources.
India plays crucial role in global pharmaceutical supply chain which would enhance its overall market share.
Indian government is also supporting the industry with Production Linked Incentive scheme and has allowed even exports as part of the scheme.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.